ClinicalTrials.gg
CompletedNCT00185328Updated Dec 12, 2008

Efficacy and Tolerability of Angeliq in Thai Women

A Phase 4 interventional study of Estradiol/DRSP (Angeliq, BAY86-4891) in Postmenopause, sponsored by Bayer. Completed. Open to female participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2008-12-12.

Sponsored by Bayer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
55
Allocation
Non-randomized
Ages
45 Years and older
Sex
Female
01

Study summary

To evaluate the safety, tolerability, and efficacy of Angeliq in Thai post menopausal women with hot flushes and other climacteric symptoms.

Read the detailed description

The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.

Bayer Schering Pharma AG, Germany is the sponsor of the trial.

02

Conditions studied

  • Postmenopause

Keywords

  • Postmenopause
03

In context

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women with hot flushes

Exclusion criteria

Exclusion Criteria:

  • Women with a for Hormone Replacement Therapy (HRT)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    Arm 1

    Drug: Estradiol/DRSP (Angeliq, BAY86-4891)

Interventions

  • DrugEstradiol/DRSP (Angeliq, BAY86-4891)

    Drug pages: Estradiol · Drospirenone

    1 tablet of 2 mg drospirenone and 1 mg estradiol, orally administered once daily, over three 28-day treatment cycles

06

What researchers measure

Primary outcomes

  1. The relative change in the frequency of hot flushes

    Time frame: At baseline, week 4, 8, 12

Secondary outcomes

  1. The change in intensity of hot flushes

    Time frame: At baseline, week 4, 8, 12

  2. The relative change in frequency of hot flushes

    Time frame: At baseline, week 4, 8

  3. The change in intensity of hot flushes

    Time frame: At baseline, week 4, 8

  4. The proportions of subjects with urogenital symptoms

    Time frame: At baseline, week 4, 8, 12

  5. Bleeding pattern

    Time frame: At baseline, week 4, 8, 12

  6. Adverse events collection

    Time frame: Collection of AE throughout the study period

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2005 and a completion of Dec 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2005
First posted
Sep 16, 2005
Start
Sep 2005
CompletionActual
Dec 2006
Last update
Dec 12, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00185328
Lead sponsor
Bayer
First posted
Sep 16, 2005
Start date
Sep 2005
Completion
Dec 2006
Last update
Dec 12, 2008

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Estradiol · Drospirenone

Start the discussion